- Patients
- Clinical Research
- Find a clinical trial
- STARSTRUCK 177Lu-TLX250-001
Solid Tumours
STARSTRUCK
Open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumours.
Trial overview
Theranostics
Solid tumours
Ib
Registration number: NCT05868174 https://www.clinicaltrials.gov/study/NCT05868174
|
Murdoch (Oncology)
St John of God Murdoch Hospital, 100 Murdoch Drive, Murdoch, WA, 6150, Australia
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
Nuclear Medicine Physician
Dr Aviral Singh
MD PGDipCard MSc FAfNM FRACP - Clinical Head of Theranostics and Nuclear Medicine
Murdoch (Oncology)

Medical Oncologist
Dr Adrian Lee
BSc (Med) MBBS (Hons) FRACP PhD
North Shore

Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.